Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“The updated ESMO guidelines for advanced and metastatic Prostate Cancer are a pleasure to read.
Huge clarity to an increasingly complex field: elegant treatment algorithms, practical guidance for clinical decisions, and recommendations that are clear about the strength of the evidence. I particularly appreciate that the authors are willing to take a position where clinicians need one.
Congratulations and thanks to Karim Fizazi and the entire international, multidisciplinary author group. This is a valuable resource for all of us caring for patients with prostate cancer, wherever we practise.
I would love to hear what colleagues around the world find most useful in the new algorithms.”
Title: Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: K. Fizazi, G. Attard, A.A. Azad, G. Baciarello, H. Beltran, A. Bjartell, P. Blanchard, F. Bossaert, E. Castro, E. Compérat, J. de Bono, A. Deschamps, E. Efstathiou, L. Emmett, S. Fanti, V. Fonteyne, A. González-del-Alba, G. Gravis, N.D. James, R. Kanesvaran, R.S. McDermott, N. Mehra, C. Parker, R.M. Renard-Penna, M.A. Rubin, F. Saad, C. Sweeney, D. Tilki, B. Tombal, A.C. Tree, J. Walz, T. Zilli, S. Gillessen
You can also read:
CIPHER Phase 2 Trial: Carboplatin in HRR-Altered Metastatic Castration-Resistant Prostate Cancer
